Express delivery and free returns within 21 days

Friday, July 1, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

NeuroCatch and BIOFLEX Partner to Research Laser Therapy for Traumatic Brain Injury

NeuroCatch (from HealthTech Connex Inc.) in Surrey, British Columbia and BIOFLEX (Meditech International Inc.) in Toronto, Ontario are pleased to announce an exciting new alliance that will advance research into the benefits of photobiomodulation therapy (PBMT) on brain health, including traumatic brain injury.

The two companies will work together to leverage their proprietary and innovative technologies, with the ultimate goal of providing health care professionals with new tools and techniques to enhance brain health and treat traumatic brain injury, including concussion.

The partnership combines the rapid, objective, quantifiable insights into cognitive brain health from Platform with the growing exploration of BIOFLEX’s photobiomodulation technologies in the areas of brain health and traumatic brain injury.

“You can’t properly treat what you can’t measure,” says BIOFLEX CEO Nicholas Olteanu. “As BIOFLEX continues its mission to help people with traumatic brain injury, NeuroCatch can provide the objective cognitive assessments we require to gauge the effectiveness of PBMT on brain health and injury, and ultimately to help gain regulatory approval for the treatment of brain injuries. Our clinics have treated well over 6,000 TBI patients with highly positive results throughout our 33-year history, and we aim to extend our knowledge to our wide customer base through this collaboration.”

BIOFLEX ® PBMT utilizes scientifically developed and clinically tested protocols that maximize the effectiveness of treatment of an extensive range of clinical conditions. PBMT technology uses superluminous and laser diodes to treat diseased or traumatized tissue with photons. These particles of energy are selectively absorbed by photoacceptors in the cell and mitochondrial membranes initiating a cascade of complex physiological reactions, leading to the restoration of normal cell physiology. The exploration of photobiomodulation therapy on traumatic brain injury is a strong focus for the company, due to the prevalence and severity of this condition, and the current lack of effective therapies.

“NeuroCatch is excited to partner with BIOFLEX ® to advance the science of brain health,” says Kirk Fisher, CEO of NeuroCatch. “With recent breakthroughs that push the limits in sensitive detection of cognitive deficits, we believe that NeuroCatch can work synergistically with the BIOFLEX ® photobiomodulation platform to help  measure the benefits of their technology as an innovative potential treatment for brain health.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
Subscribe to Medical Device News Magazine

NeuroVasc Technologies Announces First Patient Treated in Clinical Trial to Evaluate Its Novel Stent-Retriever

This trial will evaluate the safety and efficacy of the NeuroVasc ENVI™-SR, a stent-retriever intended for the treatment of acute ischemic stroke to reduce disability by removing blood clots in patients with stroke due to large vessel occlusion.

Neuromod Publishes Results of Second Large Scale Clinical Trial for Tinnitus in Top-Tier Scientific Journal

Speaking on the news, Dr Ross O’Neill, Founding CEO of Neuromod said, “We’re delighted to announce the publication of positive results from the TENT-A2 clinical trial which show greater improvement in tinnitus symptoms from treatment with Lenire. Tinnitus remains one of the largest unmet clinical needs globally and I’m proud that Neuromod is at the forefront of developing bimodal neuromodulation technology to treat chronic tinnitus.

A Randomized MRI-Based Study Reveals VasQ External Support Promotes More Stable Hemodynamics than Standard AVFs

VasQ External Support, a Laminate Medical Technologies device is implanted around the connection between the vein and artery during the creation of an arteriovenous fistula (AVF) for hemodialysis patients with the intent to provide structural reinforcement and promote a more stable flow profile.

By using this website you agree to accept Medical Device News Magazine Privacy Policy